Letter to the editor regarding: "Development of the ProPal-COPD tool to identify patients with COPD for proactive palliative care"
Pere Almagro,1 Pablo Martinez Camblor2
1Multimorbidity Patients Unit, Internal Medicine Department, Hospital Universitario Mutua de Terrassa, Universidad de Barcelona, Terrassa, Barcelona; 2The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth College, Hanover, NH, USA
We read with interest the recent article by Duenk et al entitled “Development of the ProPal-COPD tool to identify patients with COPD for proactive palliative care” recently published in the International Journal of Chronic Obstructive Pulmonary Disease.1 We fully agree with the authors on the capital importance of proactive palliative care (PPC) in COPD, as well as its underutilization. Any article that contributes to increasing knowledge of PCC and its use with COPD patients who can benefit from it is to be celebrated. We also agree with the authors on the unpredictability of prognosis in COPD, especially the uncertain evolution of severe exacerbations and the impact of comorbidities.
RG Duenk,1 C Verhagen,1 EM Bronkhorst,2 RS Djamin,3 GJ Bosman,4 E Lammers,5 PNR Dekhuijzen,6 KCP Vissers,1 Y Engels,1 Y Heijdra6
1Department of Anesthesiology, Pain and Palliative Medicine, 2Department of Health Evidence, Radboud University Medical Center, Nijmegen, 3Department of Respiratory Medicine, Amphia Hospital, Breda, 4Department of Respiratory Medicine, Slingeland Hospital, Doetinchem, 5Department of Respiratory Medicine, Gelre Hospitals, Zutphen, 6Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, the Netherlands
We thank Dr Almagro and Dr Martinez Camblor for their letter to the editor in response to our manuscript entitled “Development of the ProPal-COPD tool to identify patients with COPD for proactive palliative care”.1 We are pleased that both the authors agree with us on the importance of proactive palliative care (PPC) in COPD as well as its underutilization in this patient group. We also fully support their view that PPC should not be limited to the terminal phase of chronic diseases such as COPD but that it can be delivered alongside standard therapies, according to the needs and preferences of patients.
View the original paper by Duenk and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]